NRAS and non-small cell lung carcinoma: In order to identify signaling pathways that may compensate for MEK inhibition, and as such explain the diversity of responses to single‐agent MEK inhibition, we analyzed PI3K/Akt and mTOR signaling in the NRAS mutant NSCLC cell lines in the presence of a MEK inhibitor.